Energenesis Biomedical CoTPE:6657 +4.94%63 Altman Z-Score is 36.60 as of Jul. 04, 2026, which is 34% below its 10-year median of 55.39. GuruFocus rates TPE:6657 with a GF Score™ of 63/100 and a GF Value™ of NT$51.35 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 929 Biotechnology companies, Energenesis Biomedical Co ranks better than 92.57% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 34.35 is strong.
Energenesis Biomedical Co has a Altman Z-Score of 36.60, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Energenesis Biomedical Co's Altman Z-Score or its related term are showing as below:
TPE:6657'
s Altman Z-Score Range Over the Past 10 Years
Min: 28.99 Med: 55.39 Max: 111.45
Current: 34.35
During the past 11 years, Energenesis Biomedical Co's highest Altman Z-Score was 111.45. The lowest was 28.99. And the median was 55.39.
Energenesis Biomedical Co (TPE:6657) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6657 vs VRTX, REGN, ALNY: Altman Z-Score Comparison
For the Biotechnology subindustry, Energenesis Biomedical Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's Altman Z-Score falls into.
Energenesis Biomedical Co Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Energenesis Biomedical Co (TPE:6657) has a Altman Z-Score of 36.60 as of Jul. 04, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Energenesis Biomedical Co and its competitors. This is 34% below median its historical median of 55.39. Over the past decade, Energenesis Biomedical Co's Altman Z-Score has ranged from 28.99 to 111.45. According to the industry distribution chart, Energenesis Biomedical Co ranks #69 out of 929 companies in the Biotechnology industry, placing it in the top 7.4%.
Is Energenesis Biomedical Co's Altman Z-Score too high?
Energenesis Biomedical Co's current Altman Z-Score of 36.60 is 34% below median its 10-year median of 55.39. Over the past 10 years, this metric has ranged from a low of 28.99 to a high of 111.45. The Biotechnology industry median Altman Z-Score is 2.61. Energenesis Biomedical Co's value of 36.60 is 1302.3% above this industry median. Based on the distribution chart, Energenesis Biomedical Co ranks #69 out of 929 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Energenesis Biomedical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's Altman Z-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #69 out of 929 companies for Altman Z-Score. This places Energenesis Biomedical Co in the top 7% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.61. Energenesis Biomedical Co's value of 36.60 is 1302.3% above this benchmark. Historically, Energenesis Biomedical Co's own Altman Z-Score has ranged from 28.99 to 111.45 over the past decade. While the company's 10-year median is 55.39 vs. the industry median of 2.61, Energenesis Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.61, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Energenesis Biomedical Co's current Altman Z-Score of 36.60 is 1302.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Energenesis Biomedical Co and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Energenesis Biomedical Co's current Altman Z-Score is 36.60, which is 34% below median its own 10-year median of 55.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.35, compared to a current price of NT$37.15 — trading 27.7% below its estimated fair value. The current Altman Z-Score is 36.60, which is 34% below median its 10-year median of 55.39 and 1302.3% above the Biotechnology industry median of 2.61. Energenesis Biomedical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current Altman Z-Score is 36.60 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$37.15 is trading 27.7% below its estimated GF Value™ of NT$51.35.
GuruFocus considers Energenesis Biomedical Co to be Modestly Undervalued.
Key valuation signals for TPE:6657:
Altman Z-Score: 36.60 (34% below median its 10-year median of 55.39)
GF Value™: NT$51.35 vs. price of NT$37.15 (27.7% below fair value)
Industry Position: 1302.3% above the Biotechnology median (#69 of 929)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
63GF Score
Get the complete analysis for TPE:6657
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 
